Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA (canagliflozin) Compared to Other Diabetes Medications

Press/Media: Press / Media

PeriodJun 24 2018

Media coverage

1

Media coverage

  • TitleReal-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA (canagliflozin) Compared to Other Diabetes Medications
    Media name/outletPharmacy Choice
    CountryUnited States
    Date6/24/18
    PersonsRalph A Defronzo